Zhu Mingming, Yang Lvzhu, Kong Sufen, Bai Yuyuan, Zhao Bin
Wuhan Wecare Probiotic Research Institute, Wuhan, China.
National Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
J Food Sci. 2024 Dec;89(12):10003-10017. doi: 10.1111/1750-3841.17538. Epub 2024 Nov 26.
Probiotics play a crucial role in regulating the gut microbiota and enhancing immune response. Oral administration of probiotics modulates intestinal microbiota composition and immune homeostasis. In this study, we investigated the immunoregulatory effect of Lacticaseibacillus rhamnosus LRa05 on cyclophosphamide (CTX)-induced immunosuppressive mice. The results showed that oral administration of LRa05 reduced weight loss, restored immune organ indices, and maintained the structural integrity of the intestinal tissue in CTX-treated mice. Moreover, oral administration of LRa05 exhibited immune-modulating properties by promoting the secretion of cytokines (tumor necrosis factor-α, interleukin-1β, interleukin-10, and secretory immunoglobulin A) in serum. Moreover, the analysis of 16S rRNA amplicon sequencing revealed that LRa05 increased gut microbiota diversity and regulated its composition. In detail, LRa05 intervention restored the Firmicutes/Bacteroidota ratio and significantly increased the relative abundance of Lachnospiraceae_NK4A136_group, Oscillibacter, Alloprevotella, Parasutterella, and Roseburia in immunocompromised mice. Conversely, the abundances of Helicobacter, Bacteroides, and unclassified_Desulfovibrionaceae were significantly decreased after administration of LRa05. Based on these findings, orally administered LRa05 could effectively maintain intestinal microbiota homeostasis and regulate immunity, suggesting the potential of L. rhamnosus LRa05 as a candidate probiotic strain in the application of dietary supplement. PRACTICAL APPLICATION: Supplement with L. rhamnosus LRa05 can improve immunity, regulate gut microbiota and promote body health.
益生菌在调节肠道微生物群和增强免疫反应中起着关键作用。口服益生菌可调节肠道微生物群组成和免疫稳态。在本研究中，我们调查了鼠李糖乳杆菌LRa05对环磷酰胺（CTX）诱导的免疫抑制小鼠的免疫调节作用。结果表明，口服LRa05可减轻CTX处理小鼠的体重减轻，恢复免疫器官指数，并维持肠道组织的结构完整性。此外，口服LRa05通过促进血清中细胞因子（肿瘤坏死因子-α、白细胞介素-1β、白细胞介素-10和分泌型免疫球蛋白A）的分泌表现出免疫调节特性。此外，16S rRNA扩增子测序分析表明，LRa05增加了肠道微生物群的多样性并调节了其组成。具体而言，LRa05干预恢复了厚壁菌门/拟杆菌门的比例，并显著增加了免疫受损小鼠中毛螺菌科_NK4A136_组、颤杆菌属、别普雷沃菌属、副萨特菌属和罗斯氏菌属的相对丰度。相反，给予LRa05后，幽门螺杆菌、拟杆菌属和未分类的脱硫弧菌科的丰度显著降低。基于这些发现，口服LRa05可有效维持肠道微生物群稳态并调节免疫力，这表明鼠李糖乳杆菌LRa05作为膳食补充剂应用中的候选益生菌菌株具有潜力。实际应用：补充鼠李糖乳杆菌LRa05可提高免疫力、调节肠道微生物群并促进身体健康。
